SCN1A and Dravet syndrome: First, clinical data from patients with SCN1A‐related Dravet syndrome seem to confirm a relevant efficacy of the antisense oligonucleotide zorevunersen (former STK001),158, 159 which mediates a targeted augmentation of nuclear gene output with increased production of the productive SCN1A and functional messenger RNA (mRNA) by modulation of a splicing event.